Lot-to-lot consistency, immunogenicity, and safety of the Ad26.ZEBOV, MVA-BN-Filo Ebola virus vaccine regimen: A phase 3, randomized, double-blind, placebo-controlled trial

This phase-3, double-blind, placebo-controlled study (NCT04228783) evaluated lot-to-lot consistency of the Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen. Participants were randomized (6:6:6:1) to receive the two-dose regimen from three consecutively manufactured lots of Ad26.ZEBOV on Day 1 paired wi...

Full description

Saved in:

Bibliographic Details
Published in:	Human vaccines & immunotherapeutics Vol. 20; no. 1; p. 2327747
Main Authors:	Goldstein, Neil, McLean, Chelsea, Gaddah, Auguste, Doua, Joachim, Keshinro, Babajide, Bus-Jacobs, Linda, Hendriks, Jenny, Luhn, Kerstin, Robinson, Cynthia, Douoguih, Macaya
Format:	Journal Article
Language:	English
Published:	United States Taylor & Francis 31.12.2024 Taylor & Francis Group
Subjects:	Ad26.ZEBOV Antibodies, Viral clinical trial Double-Blind Method Ebola Ebola Vaccines Ebolavirus Hemorrhagic Fever, Ebola - prevention & control Humans immunogenicity Immunogenicity, Vaccine Licensed Vaccines MVA-BN-Filo Smallpox Vaccine Vaccination - methods vaccine Vaccines, Attenuated clinical trial Ad26.ZEBOV MVA-BN-Filo vaccine Ebola immunogenicity
ISSN:	2164-5515, 2164-554X, 2164-554X
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!